Sandoz announced on Wednesday that its asthma inhaler AirFluSal Forspiro received Danish marketing authorization following the completion of European Union decentralized procedures.
The inhaler provides a combination of salmeterol and fluticasone medications, and has proven effective after multiple clinical trials.
The inhaler is approved for treatment of patients 12 years of age or older with persistent asthma or symptomatic treatment of chronic obstructive pulmonary disease in mid- and high-strength doses.
"The first approval of AirFluSal Forspiro is a key element of our strategy to introduce differentiated generic medicines," Jeff George, the global head of Sandoz, said. "This innovative new respiratory device underscores Novartis's commitment to asthma and COPD patients and further strengthens Sandoz' global leadership in differentiated products, which comprised 43 percent of our sales in 2012."
The medication delivery system was developed at Sandoz' Center of Excellence in Rudolstadt, Germany. The company collaborated with Vectura, a United Kingdom-based company, for the product design and development.
Sandoz received the Red Dot Product Design award in 2011 for the inhaler. The inhaler uses visual control features to help the patient administer the correct dose, as well as a lever arm to load the medication.
Sandoz develops an array of medications, including generic injectables, ophthalmics, dermatology and antibiotics.